2011 NU SKIN全球大會 ageLOC抗衰老新品銷售破一億美元 併購美國生命基因科技公司 抗衰老科技如虎添翼 11.11.02
2011 NU SKIN Global Convention - ageLOC New Products Generates US$100 Million and Acquisition of LifeGen Technologies
Nu Skin Enterprises commenced its global convention at Salt Lake City, Utah in October with the announcement of new products, sales initiatives and milestones for its non-profit Foundation. At the beginning of October, Nu Skin began taking orders for the new products on a limited time basis. Orders for the new products have totaled approximately US$100 million, which was 6 times more than the previous products sales in the Global Convention 2010. Nu Skin has announced the acquisition of LifeGen Technologies which remarked the milestone of the development of ageLOC anti-aging technology. The letter of intent includes the acquisition of substantially all of the assets of LifeGen, including its tissue bank, proprietary gene expression database, patents and intellectual property related to gene research during these 30 years. In addition, Nu Skin Force for Good Foundation raised US$700,000 in the fundraising gala. And the Company’s Chairman of the Board, Blake Roney, announced that he has accepted a three-year leadership assignment to serve as a volunteer for The Church of Jesus Christ of Latter-day Saints.
At the convention, Nu Skin officially launched its latest ageLOC products, R² nutritional supplement and Galvanic Body Spa, to the more than 13,000 distributors attending convention. At the beginning of October, Nu Skin began taking orders for the new products on a limited time basis. Orders for the new products have totaled approximately US$100 million, which was 6 times more than the previous products sales in the Global Convention 2010. Nu Skin will follow-up the limited time offering with its global roll-out that will begin in the first quarter in the United States, Japan and Korea, with subsequent product introductions in Greater China and Southeast Asia in the following quarters.
In addition, Nu Skin has acquired LifeGen Technologies which remarked the milestone of the development of ageLOC anti-aging technology. The letter of intent includes the acquisition of substantially all of the assets of LifeGen, including its tissue bank, proprietary gene expression database, patents and intellectual property related to gene research during these 30 years. In connection with the transaction, the Company will also enter into consulting agreements with LifeGen Co-founders, Richard Weindruch, Ph.D., and Tomas Prolla, Ph.D., and the two will continue to serve on the Nu Skin Anti-aging Scientific Advisory Board.
“Our acquisition of LifeGen will further solidify the competitive advantage Nu Skin enjoys with our ageLOC anti-aging platform with exclusive access to LifeGen’s breakthrough work on genetic sources of aging,” said Nu Skin’s Chief Executive Officer, Truman Hunt. “The acquisition also makes financial sense as we will no longer incur royalty obligations on products developed with LifeGen’s assistance. Overall, we believe that this acquisition of LifeGen will enhance our pipeline of next-generation anti-aging products for many years to come, allowing us to provide a steady stream of innovative anti-aging solutions aimed at helping people live younger, longer.”
“LifeGen truly is a unique resource in the battle against aging,” said Dr. Joseph Chang, Nu Skin’s Chief Scientific Officer and Executive Vice President of Product Development. “Its extensive database of genetic tissue information related to the aging process and its proprietary algorithm provide the unique ability to identify aging-related genes. Few labs in the world can match this capability. We are delighted to welcome the LifeGen team to our own team of world-class scientists.”
LifeGen was jointly established by Tomas Prolla, Ph.D. and Richard Weindruch, Ph.D. The mission of LifeGen Technologies has been to discover the genetic basis of the aging process with the ultimate goal of increasing a healthy life span. LifeGen’s technology relating to the use of "gene expression profiling" as a method to measure the progression of the aging process at the molecular level in individual organs is expected to be a key component of the intellectual property to be acquired. LifeGen possesses this patent right and it also constitutes the basis of cooperation.
“We are pleased to see LifeGen joining the Nu Skin family and cementing our relationship with the Company’s research and development team as we continue to break new ground in understanding the relationship between gene activity and the nutritional control of the aging process,” said Richard Weindruch, Ph.D., Co-founder of LifeGen Technologies. “Since 2009, we have had the pleasure of working closely with Nu Skin’s research and development team. We have found significant synergies between our anti-aging expertise and Nu Skin’s innovative product development process and extensive knowledge of natural ingredients,” added Tomas Prolla, Ph.D., Co-founder of LifeGen Technologies.
2011 NU SKIN全球年會精彩片段